Lorena Alonzo-Chafart, DO
Family Medicine · Brick, NJNPI 1912998592
Payments from drug & device makers
Across 187 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$450
- Lilly USA, LLC$352
- Exact Sciences$262
- Abbott$247
- Novo Nordisk$216
- Daiichi Sankyo Inc.$181
- plus $2K from 25 others
What the payments were for
- Travel & lodging$181%
- Food & beverage$3,22799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $450 |
| Lilly USA, LLC | 22 | $352 |
| Exact Sciences | 9 | $262 |
| Abbott | 12 | $247 |
| Novo Nordisk | 13 | $216 |
| Daiichi Sankyo Inc. | 13 | $181 |
| Pfizer | 3 | $149 |
| Novartis | 10 | $147 |
| Kowa Pharmaceuticals America, Inc. | 10 | $136 |
| AstraZeneca | 8 | $129 |
| Amarin Pharma, Inc. | 9 | $127 |
| Astellas Pharma US Inc | 8 | $123 |
| Amgen | 7 | $99 |
| Johnson & Johnson | 5 | $88 |
| Bayer | 4 | $83 |
| Topcon Healthcare Solutions, Inc. | 1 | $81 |
| Biohaven Pharmaceuticals, Inc. | 1 | $65 |
| Merck | 4 | $52 |
| Esperion Therapeutics, Inc. | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Aytu Biopharma, Inc. | 2 | $29 |
| Corcept Therapeutics | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$119
How this compares
$3,245 in reported general payments places this provider in the 80th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $63,763 |
| EliquisApixaban | 39 | $54,269 |
| JanuviaSitagliptin Phosphate | 17 | $26,681 |
| MounjaroTirzepatide | 23 | $21,626 |
| VraylarCariprazine Hcl | 13 | $16,767 |
| ViberziEluxadoline | 12 | $9,450 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,270 |
| LinzessLinaclotide | 11 | $7,654 |
| Levothyroxine Sodium | 427 | $4,986 |
| Rosuvastatin Calcium | 310 | $4,506 |
| SynthroidLevothyroxine Sodium | 72 | $4,454 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $3,965 |
| Losartan Potassium | 263 | $3,457 |
| Lidocaine | 22 | $3,290 |
| Pantoprazole Sodium | 185 | $2,927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $216 | $63,76354 claims |
| PfizerEliquis | $149 | $54,26939 claims |
| AbbVieVraylar, Viberzi, Linzess, Synthroid | $450 | $38,326108 claims |
| MerckJanuvia | $52 | $26,68117 claims |
| Lilly USA, LLCMounjaro | $352 | $21,62623 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $4,986427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Brick
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.